Menu
"Advancing the development and approval of novel therapeutics by providing built-for-purpose immunoassays."
At Xeno Diagnostics, our ultimate goal is to get new medical therapies into the hands of providers. We accomplish our mission by helping our clients – organizations in biotech and pharma – with both product development and in moving their technologies through the regulatory approval process. We specialize in assays that assess the safety and efficacy of these novel technologies. Our lab was designed and our staff trained to handle the rigorous challenges presented by adherence to regulatory requirements, as well as the challenges presented in analyzing unique products; from bio-implantable materials and stem-cell therapies to the more traditional small- and large-molecule drug candidates. Xeno has developed effective processes and assays to address the distinct challenges each technology presents, keeping those qualified technologies on their path to the patients’ bedsides.
Xeno Diagnostics, LLC was established in 2007 with the purpose of providing products and services to aid in the use of pigs in transplantation and basic research. Xeno’s success in establishing ELISA, PCR, cell culture assays, and antibody development led to clients requesting assistance with other cell-based assays utilizing other animal species. Xeno expanded its focus to meet those needs as well as addressing unique requests from industry, academia, and startup companies. Additional cell-based assays were developed to evaluate emerging technologies ranging from implantable tissues and biosynthetic materials to test compounds aimed at treating cancers, virii, and other diseases. Currently available assays include but are not limited to: Mixed Lymphocyte Reactions (MLR’s), Cytotoxicity Assays (CDC/ADCC), Cytokine Release, Receptor Occupancy Assays, and Immunoglobulin Quantification.
Xeno Diagnostics obtained its high complexity CLIA accreditation in 2008, and through participation in the external inspection process it maintains high standards in laboratory testing. Clients also benefit from Xeno’s related organizational infrastructure including its relationships with other CRO’s, IRB’s, patient recruitment organizations, animal product providers (body fluids, tissues, cells), and biorepositories. These collaborations have enabled Xeno to successfully handle a greater variety of projects while saving our clients time.
Dan Follas, MS, is CEO at Xeno Diagnostics. He received his MS from the Department of Medicinal Chemistry & Pharmacognosy, Purdue University. He worked as a Research Associate at the Indiana University Medical Center, Indianapolis, IN prior to starting Follas Laboratories in 1979 serving as President and CEO. After selling Follas Labs in 2006, Dan started Xeno Diagnostics in 2007.
Dan received his doctorate in Pharmacology & Toxicology from the University of Kansas Medical School. Prior to joining XD in 2014, his experience included teaching at the Chemical Research Institute for Toxicology and industrial experience as Research Scientist at Eli Lily in the areas of immunotoxicology and immunogenicity.
Jon began his career at XD as a laboratory technologist in 2010 after receiving his degree from Xavier University. During this time Jon also developed expertise in multiple administrative areas and assumed the position of Chief Operations Officer in 2014. Continued development in laboratory operations lead to him assuming the role of President in 2017.
Mika received her doctorate in Science and Technology from Kobe University, Japan. She worked as Lab Director/Embryologist at the Koshida Clinic, Osaka, Japan prior to taking a Postdoctoral Fellowship at the Animal Science Research Center at the University of Missouri-Columbia, Columbia, Mo. She joined Xeno Diagnostics in 2018.
Andrew received his doctorate from the Department of Chemistry at the University of Virginia in 2020. As a member of the XD scientific staff since 2020 as a Research Scientist, he has managed several client projects including custom assay development and biomaterial analysis.
Steve received his doctorate from The University of Missouri-Columbia, with a focus in Cryobiology. Prior to joining Xeno in 2024, Steve served on the Executive Committee for the Society for Cryobiology, and continues to serve as a Member of the Editorial Boards of two Journals, Cryobiology and CryoLetters. Steve also has decades of industry experience, working for multiple medical device manufacturers.
After receiving his BS in Laboratory Medicine at Far Eastern University, Manila, Philippines, Antonio received his ASCP from the North Kansas City Memorial Hospital, North Kansas City, Missouri. He worked as a Supervisor/Manager for Methodist Hospital, Covance Laboratories, and Follas Laboratories prior to joining XD in 2014.
While working as a Specialist in Department of Laboratory Medicine at Children’s Hospital, Dave earned his doctorate in clinical chemistry in the Department of Pathology at The Ohio State University. He subsequently assumed the position of Director of the Clinical Chemistry Laboratory at Nationwide Children’s Hospital in Columbus, Ohio while also assuming the position of Laboratory Director for XD in 2008.
Dick received his PhD from the University of Cincinnati in 1981 and completed post-doctoral fellowships at Vanderbilt University and Indiana University. He subsequently served as Director of Flow Cytometry at the Indiana University Health Transplant Institute. Dick has provided flow cytometry expertise to XD since 2007.
Rob received his Bachelor’s in Biology and Chemistry from Denison University, in Granville, OH. He went on to further his education and experience in the strategy and execution for Contract Research Organizations. He brings to Xeno Diagnostics decades of experience in market assessment, team-building, contract negotiations, and enhancing client relationships in the pharmaceutical, biotech, and diagnostics industries.
Xeno Diagnostics is proud to call itself the home of many talented and dynamic employees. We understand that our success starts with the quality of our employees. If you are interested in joining our team, feel free to submit a CV and cover letter.
Copyright © 2021. All rights reserved.
